Stefan Kluge1, Jakob J Malin, Falk Fichtner, Oliver J Müller, Nicole Skoetz, Christian Karagiannidis. 1. * Guideline Development Group see eBox; Department of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department I of Internal Medicine, Division of Infectious Diseases, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany; Department of Anesthesiology and Intensive Care Medicine, University of Leipzig Medical Center, Leipzig, Germany; Department of Internal Medicine III, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany; Department of Pneumology and Critical Care Medicine, Cologne-Merheim Hospital, Cologne, Germany.
Abstract
BACKGROUND: The mortality of COVID-19 patients who are admitted to a hospital because of the disease remains high. The implementation of evidence-based treatments can improve the quality of care. METHODS: The new clinical practice guideline is based on publications retrieved by a systematic search in the Medline databases via PubMed and in the Cochrane COVID-19 trial registry, followed by a structured consensus process leading to the adoption of graded recommendations. RESULTS: Therapeutic anticoagulation can be considered in patients who do not require intensive care and have an elevated risk of thromboembolism (for example, those with D-dimer levels ≥ 2 mg/L). For patients in intensive care, therapeutic anticoagulation has no benefit. For patients with hypoxemic respiratory insufficiency, prone positioning and an early therapy attempt with CPAP/noninvasive ventilation (CPAP, continuous positive airway pressure) or high-flow oxygen therapy is recommended. Patients with IgG-seronegativity and, at most, low-flow oxygen should be treated with SARS-CoV-2-specific monoclonal antibodies (at present, casirivimab and imdevimab). Patients needing no more than low-flow oxygen should additionally be treated with janus kinase (JAK) inhibitors. All patients who need oxygen (low-flow, high-flow, noninvasive ventilation/CPAP, invasive ventilation) should be given systemic corticosteroids. Tocilizumab should be given to patients with a high oxygen requirement and progressively severe COVID-19 disease, but not in combination with JAK inhibitors. CONCLUSION: Noninvasive ventilation, high-flow oxygen therapy, prone positioning, and invasive ventilation are important elements of the treatment of hypoxemic patients with COVID-19. A reduction of mortality has been demonstrated for the administration of monoclonal antibodies, JAK inhibitors, corticosteroids, tocilizumab, and therapeutic anticoagulation to specific groups of patients.
BACKGROUND: The mortality of COVID-19 patients who are admitted to a hospital because of the disease remains high. The implementation of evidence-based treatments can improve the quality of care. METHODS: The new clinical practice guideline is based on publications retrieved by a systematic search in the Medline databases via PubMed and in the Cochrane COVID-19 trial registry, followed by a structured consensus process leading to the adoption of graded recommendations. RESULTS: Therapeutic anticoagulation can be considered in patients who do not require intensive care and have an elevated risk of thromboembolism (for example, those with D-dimer levels ≥ 2 mg/L). For patients in intensive care, therapeutic anticoagulation has no benefit. For patients with hypoxemic respiratory insufficiency, prone positioning and an early therapy attempt with CPAP/noninvasive ventilation (CPAP, continuous positive airway pressure) or high-flow oxygen therapy is recommended. Patients with IgG-seronegativity and, at most, low-flow oxygen should be treated with SARS-CoV-2-specific monoclonal antibodies (at present, casirivimab and imdevimab). Patients needing no more than low-flow oxygen should additionally be treated with janus kinase (JAK) inhibitors. All patients who need oxygen (low-flow, high-flow, noninvasive ventilation/CPAP, invasive ventilation) should be given systemic corticosteroids. Tocilizumab should be given to patients with a high oxygen requirement and progressively severe COVID-19 disease, but not in combination with JAK inhibitors. CONCLUSION: Noninvasive ventilation, high-flow oxygen therapy, prone positioning, and invasive ventilation are important elements of the treatment of hypoxemic patients with COVID-19. A reduction of mortality has been demonstrated for the administration of monoclonal antibodies, JAK inhibitors, corticosteroids, tocilizumab, and therapeutic anticoagulation to specific groups of patients.
Authors: Hongchao Pan; Richard Peto; Ana-Maria Henao-Restrepo; Marie-Pierre Preziosi; Vasee Sathiyamoorthy; Quarraisha Abdool Karim; Marissa M Alejandria; César Hernández García; Marie-Paule Kieny; Reza Malekzadeh; Srinivas Murthy; K Srinath Reddy; Mirta Roses Periago; Pierre Abi Hanna; Florence Ader; Abdullah M Al-Bader; Almonther Alhasawi; Emma Allum; Athari Alotaibi; Carlos A Alvarez-Moreno; Sheila Appadoo; Abdullah Asiri; Pål Aukrust; Andreas Barratt-Due; Samir Bellani; Mattia Branca; Heike B C Cappel-Porter; Nery Cerrato; Ting S Chow; Najada Como; Joe Eustace; Patricia J García; Sheela Godbole; Eduardo Gotuzzo; Laimonas Griskevicius; Rasha Hamra; Mariam Hassan; Mohamed Hassany; David Hutton; Irmansyah Irmansyah; Ligita Jancoriene; Jana Kirwan; Suresh Kumar; Peter Lennon; Gustavo Lopardo; Patrick Lydon; Nicola Magrini; Teresa Maguire; Suzana Manevska; Oriol Manuel; Sibylle McGinty; Marco T Medina; María L Mesa Rubio; Maria C Miranda-Montoya; Jeremy Nel; Estevao P Nunes; Markus Perola; Antonio Portolés; Menaldi R Rasmin; Aun Raza; Helen Rees; Paula P S Reges; Chris A Rogers; Kolawole Salami; Marina I Salvadori; Narvina Sinani; Jonathan A C Sterne; Milena Stevanovikj; Evelina Tacconelli; Kari A O Tikkinen; Sven Trelle; Hala Zaid; John-Arne Røttingen; Soumya Swaminathan Journal: N Engl J Med Date: 2020-12-02 Impact factor: 91.245
Authors: Patrick R Lawler; Ewan C Goligher; Jeffrey S Berger; Matthew D Neal; Bryan J McVerry; Jose C Nicolau; Michelle N Gong; Marc Carrier; Robert S Rosenson; Harmony R Reynolds; Alexis F Turgeon; Jorge Escobedo; David T Huang; Charlotte A Bradbury; Brett L Houston; Lucy Z Kornblith; Anand Kumar; Susan R Kahn; Mary Cushman; Zoe McQuilten; Arthur S Slutsky; Keri S Kim; Anthony C Gordon; Bridget-Anne Kirwan; Maria M Brooks; Alisa M Higgins; Roger J Lewis; Elizabeth Lorenzi; Scott M Berry; Lindsay R Berry; Aaron W Aday; Farah Al-Beidh; Djillali Annane; Yaseen M Arabi; Diptesh Aryal; Lisa Baumann Kreuziger; Abi Beane; Zahra Bhimani; Shailesh Bihari; Henny H Billett; Lindsay Bond; Marc Bonten; Frank Brunkhorst; Meredith Buxton; Adrian Buzgau; Lana A Castellucci; Sweta Chekuri; Jen-Ting Chen; Allen C Cheng; Tamta Chkhikvadze; Benjamin Coiffard; Todd W Costantini; Sophie de Brouwer; Lennie P G Derde; Michelle A Detry; Abhijit Duggal; Vladimír Džavík; Mark B Effron; Lise J Estcourt; Brendan M Everett; Dean A Fergusson; Mark Fitzgerald; Robert A Fowler; Jean P Galanaud; Benjamin T Galen; Sheetal Gandotra; Sebastian García-Madrona; Timothy D Girard; Lucas C Godoy; Andrew L Goodman; Herman Goossens; Cameron Green; Yonatan Y Greenstein; Peter L Gross; Naomi M Hamburg; Rashan Haniffa; George Hanna; Nicholas Hanna; Sheila M Hegde; Carolyn M Hendrickson; R Duncan Hite; Alexander A Hindenburg; Aluko A Hope; James M Horowitz; Christopher M Horvat; Kristin Hudock; Beverley J Hunt; Mansoor Husain; Robert C Hyzy; Vivek N Iyer; Jeffrey R Jacobson; Devachandran Jayakumar; Norma M Keller; Akram Khan; Yuri Kim; Andrei L Kindzelski; Andrew J King; M Margaret Knudson; Aaron E Kornblith; Vidya Krishnan; Matthew E Kutcher; Michael A Laffan; Francois Lamontagne; Grégoire Le Gal; Christine M Leeper; Eric S Leifer; George Lim; Felipe Gallego Lima; Kelsey Linstrum; Edward Litton; Jose Lopez-Sendon; Jose L Lopez-Sendon Moreno; Sylvain A Lother; Saurabh Malhotra; Miguel Marcos; Andréa Saud Marinez; John C Marshall; Nicole Marten; Michael A Matthay; Daniel F McAuley; Emily G McDonald; Anna McGlothlin; Shay P McGuinness; Saskia Middeldorp; Stephanie K Montgomery; Steven C Moore; Raquel Morillo Guerrero; Paul R Mouncey; Srinivas Murthy; Girish B Nair; Rahul Nair; Alistair D Nichol; Brenda Nunez-Garcia; Ambarish Pandey; Pauline K Park; Rachael L Parke; Jane C Parker; Sam Parnia; Jonathan D Paul; Yessica S Pérez González; Mauricio Pompilio; Matthew E Prekker; John G Quigley; Natalia S Rost; Kathryn Rowan; Fernanda O Santos; Marlene Santos; Mayler Olombrada Santos; Lewis Satterwhite; Christina T Saunders; Roger E G Schutgens; Christopher W Seymour; Deborah M Siegal; Delcio G Silva; Manu Shankar-Hari; John P Sheehan; Aneesh B Singhal; Dayna Solvason; Simon J Stanworth; Tobias Tritschler; Anne M Turner; Wilma van Bentum-Puijk; Frank L van de Veerdonk; Sean van Diepen; Gloria Vazquez-Grande; Lana Wahid; Vanessa Wareham; Bryan J Wells; R Jay Widmer; Jennifer G Wilson; Eugene Yuriditsky; Fernando G Zampieri; Derek C Angus; Colin J McArthur; Steven A Webb; Michael E Farkouh; Judith S Hochman; Ryan Zarychanski Journal: N Engl J Med Date: 2021-08-04 Impact factor: 176.079
Authors: Jan Andreas Kloka; Lea Valeska Blum; Oliver Old; Kai Zacharowski; Benjamin Friedrichson Journal: Sci Rep Date: 2022-07-01 Impact factor: 4.996
Authors: Jakob J Malin; Christoph D Spinner; Uwe Janssens; Tobias Welte; Steffen Weber-Carstens; Gereon Schälte; Petra Gastmeier; Florian Langer; Martin Wepler; Michael Westhoff; Michael Pfeifer; Klaus F Rabe; Florian Hoffmann; Bernd W Böttiger; Julia Weinmann-Menke; Alexander Kersten; Peter Berlit; Marcin Krawczyk; Wiebke Nehls; Falk Fichtner; Sven Laudi; Miriam Stegemann; Nicole Skoetz; Monika Nothacker; Gernot Marx; Christian Karagiannidis; Stefan Kluge Journal: Infection Date: 2021-07-06 Impact factor: 3.553